Glucagon Mechanism: In-depth Analysis of Its Action in Hypoglycemia
Published: 15 7 月, 2026 19:17
Author: Robert Cannon
Abstract: Glucagon, a 29-amino acid peptide, counteracts hypoglycemia by activating hepatic G-protein-coupled receptors, stimulating glycogenolysis and gluconeogenesis. Market trends show a 7.2% CAGR (2023-2030) driven by diabetes prevalence and biosimilar adoption. Leading brands (GlucaGen, Baqsimi) differ in delivery (injectable vs. intranasal) and stability. Nasal glucagon offers faster absorption but higher cost. Key selection criteria include purity (>98%), cold-chain logistics (2-8°C), and FDA/EMA certifications. Industry challenges include manufacturing complexity and short shelf-life.